Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease
Launched by UNIVERSITY OF ROCHESTER · Dec 7, 2022
Trial Information
Current as of January 22, 2025
Active, not recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosis of chronic of kidney disease
- • have eGFR 20-59 mL/min/1.73m2 at the time of enrollment
- • parents must be able to provide consent
- Exclusion Criteria:
- • weight \<30 kg
- • cancer or HIV diagnosis
- • history of solid organ transplantation (including kidney transplant)
- • structural heart disease
- • currently pregnant or plan to become pregnant
- • life expectancy is less than one year
- • Patients will also be excluded if they are currently taking anticoagulants, immunosuppression, or chemotherapeutics
About University Of Rochester
The University of Rochester is a leading academic institution dedicated to advancing medical research and improving patient care through innovative clinical trials. Renowned for its commitment to excellence in education, research, and clinical practice, the university fosters a collaborative environment that integrates cutting-edge scientific inquiry with practical applications in healthcare. With a focus on diverse therapeutic areas, the University of Rochester aims to enhance treatment options and outcomes for patients while contributing to the broader scientific community through rigorous study design and ethical standards in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, New York, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials